Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T), and dexamethasone (D) on overall survival (OS), event-free survival (EFS), time to next therapy, and post-relapse survival in Total Therapy 3 were examined, using time-dependent methodology,...

Full description

Saved in:
Bibliographic Details
Main Authors: van Rhee, Frits, Szymonifka, Jackie, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Barlogie, Bart
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2010
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938233/
https://ncbi.nlm.nih.gov/pubmed/20501894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-01-264333
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items